Former Lululemon Executive Joins True Leaf as Chief Financial Officer

DGAP-News: True Leaf Medicine International Ltd. / Key word(s): Market launch/Change of Personnel

20.09.2018 / 13:10

The issuer is solely responsible for the content of this announcement.


Former Lululemon Executive Joins True Leaf as Chief Financial Officer

Kerry Biggs brings NASDAQ-level finance and operations experience at pivotal time in company’s growth

VERNON, BCSeptember 20, 2018 – True Leaf Medicine International Ltd. (“True Leaf”) (CSE: MJ) (OTCQB: TRLFF) (FSE: TLA), a plant-forward wellness brand for people and their pets, today announced the appointment of Kerry Biggs, CPA, MBA, as Chief Financial Officer.

Mr. Biggs has more than 20 years of finance and business experience, most recently with lululemon athletica, where he was Vice President, Treasurer looking after capital markets, liquidity, treasury, insurance and risk activities for the NASDAQ-listed company. Previously, he served as Vice President, Finance at Global Container Terminals where he was responsible for capital markets, risk management, accounting, tax planning, and corporate M&A activities. He also worked in senior finance roles for Finning International and Enbridge, both large publicly traded companies.

“Mr. Biggs has held leadership roles for several prominent Canadian public companies with premium global brands,” said Darcy Bomford, Founder and Chief Executive Officer of True Leaf. “He has a strong understanding of a business’s key performance drivers and a solid history of adding value by driving operational efficiencies. This experience will be invaluable to True Leaf as we continue to grow exponentially.”

“Joining True Leaf is a unique opportunity to work for a strong company with a leading position in the high-growth pet and cannabis markets, and with an established global distribution of its legal products,” said Kerry Biggs, Chief Financial Officer of True Leaf. “I am most looking forward to working with the team to tell True Leaf’s growth story to the market.”

Mr. Biggs holds an MBA from the Richard Ivey School of Business (University of Western Ontario), a Chartered Professional Accountant designation, and a Bachelor of Arts, Political Science degree from the University of Victoria.

The Company also announced it has granted stock options to officers and consultants to purchase up to a total 1,050,000 common shares, exercisable at a price of 56 cents per share, which was the closing price of the Company’s shares on September 10, 2018, being the date of grant. The majority of the stock options are exercisable for five years until September 10, 2023.

About True Leaf

True Leaf is a plant-forward wellness brand for people and their pets. Founded in 2013, True Leaf has two main operating divisions: True Leaf Medicine Inc. and True Leaf Pet Inc.

True Leaf Medicine Inc. is in the final stages of approval to become a licensed producer of federally-approved medicinal cannabis for the Canadian market. The license is subject to a Health Canada inspection to allow for the production, manufacture, and distribution of cannabis products upon the completion of the Company’s cannabis cultivation facility being built in Lumby, British Columbia. The facility is expected to be completed in fall 2018.

Established in 2015, True Leaf Pet Inc. is one of the first companies to market hemp-based products for pets worldwide. The Company is initially marketing a line of hemp-seed based supplements for pets. True Hemp(TM) chews, dental sticks, and supplement oils are sold in more than 2,000 stores across North America and Europe.

www.trueleaf.com

Media Contact:

Paul Sullivan
Director, Public Relations
Paul@trueleaf.com
O: 604-685-4742
M: 604-603-7358

Investor Contact:

Kevin Bottomley (Canada)
Director and Corporate Relations
Kevin@trueleaf.com
M: 778-389-9933

Tirth Patel (US)
Edison Advisors
tpatel@edisongroup.com
O: 646-653-7035

Follow True Leaf

twitter.com/trueleafpet

facebook.com/trueleafpet

instagram.com/trueleafpet

Forward-Looking Statements

This news release contains forward-looking statements and management may make additional forward-looking statements in response to your questions. Such written and oral disclosures are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995 and True Leaf hereby claims such safe harbour protection for all forward-looking statements. True Leaf believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions; however, True Leaf’s actual results and performance and the value of its securities could differ materially from those set forth in the forward-looking statements due to the impact of many factors summarized in the “Risk Factors” section of True Leaf’s Offering Circular Form 1-A filed with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities and other discussions of risk factors contained in True Leaf’s periodic filings or supplements to the offering circular. True Leaf’s Offering Circular Form 1-A can be found at www.trueleaf.com/pages/investor. Forward-looking statements speak only as of the date they are made. True Leaf undertakes no obligation to update or revise any such information for any reason after the date of this presentation unless required by law.


20.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: True Leaf Medicine International Ltd.
32 – 100 Kalamalka Lake Road
V1T 9 G1 Vernon (BC)
Canada
Phone: +17783899933
E-mail: kevin@trueleaf.com
Internet: www.trueleaf.com
ISIN: CA89785C1077, CA89785C1077
WKN: , A0Q3EE
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Canadian Venture Exchange

 
End of News DGAP News Service

show this

Hardman & Co Research: Oxford BioMedica (OXB): Partnering strategy delivering profitability

Hardman & Co Research

20-Sep-2018 / 10:55 GMT/BST


Hardman & Co: Partnering strategy delivering profitability

OXB is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, while retaining proprietary drug candidates. OXB will also receive royalties on commercial products developed with its LentiVector(R) platform. The first half of 2018 delivered significant growth in gross income, primarily through licensing income on signing new partnership deals with Axovant Sciences (AXON) and Bioverativ (BIVV). OXB out-licensed its proprietary Parkinson’s gene-therapy to AXON in a $842.5m deal, and the $105m BIVV deal is for haemophilia gene-therapy development.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/20.09.18-partnering-strategy-delivering-profitability.pdf

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter @HardmanandCo

Contacts:

Dr Martin Hall
Dr Dorothea Hill
Dr Gregoire Pave

+44 20 7194 7622

mh@hardmanandco.com
dmh@hardmanandco.com
gp@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies’ profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

show this

Fresenius Medical Care included for 10th consecutive year in Dow Jones Sustainability Index

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous

20.09.2018 / 09:21

The issuer is solely responsible for the content of this announcement.


Fresenius Medical Care, the world’s largest provider of dialysis products and services, has been recognized for the 10th consecutive year as a sustainability leader with inclusion in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent of the largest 600 European companies in the S&P Global BMI, based on the international investment company RobecoSAM’s analysis of their economic, environmental and social performance.

This year, Fresenius Medical Care scored particularly highly for its reporting on environmental and social issues as well as its materiality analysis, which identifies issues in the economy, environment and society that may significantly affect a company’s performance. With publication of its first non-financial group report in 2018, Fresenius Medical Care has also established a global sustainability governance structure. This will further improve the coordination and management of sustainability topics across all regions.

Rice Powell, Chief Executive Officer of Fresenius Medical Care and head of the company’s Sustainability Decision Board, said: “Over the past years, we have continuously built up our sustainability efforts, as we are convinced that acting in a responsible and sustainable manner goes hand in hand with our commercial success. Being included in the renowned Dow Jones Sustainability Index for 10 years in a row makes us proud, and confirms that we are on the right track by putting patients first.”

Fresenius Medical Care is the world’s largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,815 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 325,188 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company’s website at www.freseniusmedicalcare.com.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.


20.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.freseniusmedicalcare.com
ISIN: DE0005785802
WKN: 578580
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange

 
End of News DGAP News Service

show this

4SC AG: Domatinostat plus chemotherapy – Overcoming drug resistance

DGAP-News: 4SC AG / Key word(s): Conference

20.09.2018 / 07:30

The issuer is solely responsible for the content of this announcement.


4SC AG: Domatinostat plus chemotherapy – Overcoming drug resistance

  • Domatinostat (4SC-202) renders cancer cell lines more susceptible to chemotherapy treatment
  • Poster presentation at the SIC Annual Meeting, 19-22 September 2018, Milan, Italy

 

Planegg-Martinsried, Germany, 20 September 2018 – Preclinical data showing that a combination of 4SC AG’s (4SC, FSE Prime Standard: VSC) domatinostat (4SC-202) with chemotherapy increased inhibition of cell growth when compared to treatment with either alone will be presented at the 60th Annual Meeting of the Italian Cancer Society (SIC), held on 19-22 September 2018 in Milan, by 4SC’s collaborator Alfredo Budillon, M.D., Ph.D., Head of the Experimental Pharmacology Unit in the Department of Research at the Istituto Nazionale Tumori IRCCS “Fondazione Pascale” in Naples, Italy. The poster will be available on 4SC’s website after the presentation.

Alfredo Budillon summarized the experiments: “In order to improve therapeutic efficacy of conventional treatment, we tested potential combination strategies of the class I specific histone deacetylase inhibitor domatinostat plus chemotherapy regimens such as gemicitabine/paclitaxel or fluoropyrimidines/irinotecan (FOLFIRI) in several pancreatic cancer models. We already observed anti-tumoral effects on the cancer cell lines such as inhibition of tumor growth and induction of cell death using domatinostat alone. By combining domatinostat with chemotherapy regimens we saw synergistically increased inhibition of cell growth compared to single treatment with either domatinostat or chemotherapy, producing best results when domatinostat was added 24 hours prior to chemotherapy.”

4SC is currently evaluating domatinostat in combination with the checkpoint inhibitor pembrolizumab, a form of immunotherapy, in the Phase Ib/II clinical SENSITIZE study in advanced melanoma patients. Earlier this year, 4SC published preclinical data which demonstrated increased tumor control, durable responses and increased survival of mice treated with domatinostat in combination with several classes of immuno-therapeutics.

Frank Hermann, M.D., Chief Development Officer of 4SC, said: “We thank our collaborators for their enthusiasm and energy in their research work with domatinostat. The addition of this new preclinical data on the combination of domatinostat with several forms of chemotherapy underlines domatinostat’s potential to be a promising combination partner, for example to overcome drug resistance to different treatment classes in cancer. Based on these promising results, we are evaluating further clinical trials of domatinostat in various combinations.”

Abstract #E3: 4SC-202 (domatinostat), a novel histone deacetylase inhibitor, improves chemotherapy efficacy and overcomes drug resistance in pancreatic cancer models.

Date: 20 and 21 September 2018
Time: 12:00 – 13:00
Location: Poster Viewing area; Università degli Studi di Milano

 

– Press release ends –

 

Related articles

15 August 2018, 4SC AG: FDA approves IND application for domatinostat (4SC-202) in melanoma

31 July 2018, First patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma

17 April 2018, 4SC at AACR: Broadened clinical options for 4SC-202

 

Further information

 

About domatinostat (4SC-202)

Domatinostat is an orally administered small molecule Class I selective HDAC inhibitor with a unique mode of action that was designed to strengthen the body’s own anti-tumor immune response. Domatinostat also influences the tumor microenvironment facilitating infiltration of immune cells into the tumor and making it more visible to the immune system.

Domatinostat has been investigated in a Phase I study with 24 heavily pretreated patients with several types of advanced hematologic cancers and was well tolerated. Positive signs of anti-tumor efficacy were also observed; with one complete remission (28 months) and one partial responder (8 months).

In addition to its therapeutic potential in cancer monotherapy, 4SC is evaluating domatinostat’s capacity as a partner in combination therapies, specifically in the immuno-oncology area. In this respect, 4SC initiated a Phase Ib/II study of domatinostat in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab in patients with advanced-stage melanoma. A second Phase II study of domatinostat in combination with the anti-PD-L1 checkpoint inhibitor avelumab, which will be conducted by an academic partner in gastrointestinal cancers, is expected to start soon.

As soon as results from the aforementioned trials will be available, 4SC plans to advance domatinostat into a pivotal study in combination with a checkpoint inhibitor in PD-(L)1 refractory patients with advanced Merkel cell carcinoma (MCC).

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises three key drug candidates in various stages of preclinical and clinical development: resminostat, domatinostat (4SC-202) and 4SC-208.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 45 employees as of 30 June 2018 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

 

Contact

4SC
Anna Niedl, Ph.D., CIRO
Corporate Communications & Investor Relations
anna.niedl@4sc.com
+49 89 700763-66

LifeSci Advisors
Hans Herklots
Managing Director
hherklots@lifesciadvisors.com
+41 79 598 7149


20.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Germany
Phone: +49 89 700763-0
Fax: +49 89 700763-29
E-mail: public@4sc.com
Internet: www.4sc.com
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Secarna Pharmaceuticals successfully hosted Inaugural Industry Expert Meeting and Networking Event for the Oligonucleotide Therapeutics Society (OTS) in Munich

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Conference

19.09.2018 / 11:30

The issuer is solely responsible for the content of this announcement.


Secarna Pharmaceuticals successfully hosted Inaugural Industry Expert Meeting and Networking Event for the Oligonucleotide Therapeutics Society (OTS) in Munich
 

  • Secarna provided a platform for discussion and information on antisense therapeutics with highly regarded experts from industry and academia
  • Event highlighted importance of antisense therapeutics as third pillar of drug development, in addition to small molecules and monoclonal antibodies
  • Latest generation antisense technologies such as Secarna’s LNAplusTM are going to lead to innovative, highly specific, safe and efficacious therapies for challenging or currently undruggable targets

Munich/Martinsried, Germany, September 19, 2018 – Secarna Pharmaceuticals, a new breed biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets in a number of organ systems, announced today that it has successfully hosted the inaugural Oligonucleotide Therapeutics Society (OTS) industry expert meeting and networking event in Munich titled “Oligonucleotides – Paving the path for a new generation of therapeutics”. The event took place on September 18 at the Innovations- und Gründerzentrum Biotechnologie (IZB) in Martinsried and featured top-level speakers highlighting the enormous importance of new therapeutics based on antisense oligonucleotides (ASO) as the third pillar of drug development, in addition to small molecules and monoclonal antibodies.

A total of 63 participants used the opportunity to get cutting-edge information on the discovery and development of ASO therapeutics in talks delivered by Rainer Wessel, Former Executive Management of Ganymed Pharmaceuticals AG/Astellas Pharma Inc., Frank Jaschinski, Chief Scientific Officer at Secarna Pharmaceuticals GmbH & Co. KG, Christian Schetter, Chief Executive Officer at Rigontec GmbH / a MSD Company , Kirsten Vonde from Granzer Regulatory Consulting & Services and Thomas Rupp from Thomas Rupp Consulting (CMC). Afterwards, the speakers and participants discussed the future of antisense technologies in a Q&A session.

Frank Jaschinski, Chief Scientific Officer at Secarna Pharmaceuticals GmbH & Co. KG, stated: “Oligonucleotide-based drugs such as antisense oligonucleotides have a great potential to become a major therapeutic modality complimentary to small molecules and protein or antibody-based drugs. The industry faces its technical challenges but addressing these challenges results in safe and efficacious antisense drugs for challenging or currently undruggable targets.”

Kirsten Vonde from Granzer Regulatory Consulting & Services, said: “We see many interesting developments in clinical and preclinical studies. Let’s keep our fingers crossed that they make it over the hurdle.” Vonde introduced the audience to the regulatory aspects of antisense oligonucleotide development and how to proceed within the regulatory process for clinical development. And Christian Schetter, Chief Executive Officer at Rigontec GmbH / a MSD Company, added: “The ultimate success of a technology will be to reach patients and play a major role in the market place. An acquisition by a large pharma player with significant resources in global development significantly increases the probability of such an outcome and is therefore a success” in his talk about the development of oligonucleotides in the clinic and shared Rigontec’s successes and key learnings throughout the acquisition by MSD.

Highly-relevant insights into a rapidly growing pharmaceutical market segment

“We are proud to have hosted this first networking event of this kind in Munich and to have provided an impressive platform for discussion and information exchange with such highly regarded antisense therapeutics experts. The large number of participants, the interesting presentations and lively discussions reflect the quality of antisense oligonucleotide research in Germany,” said Jonas Renz, Managing Director and Co-founder of Secarna. “Over the last three years, we have seen a significant increase in antisense drug approvals which, together with a meaningful number of clinical development candidates, impressively portray the increasing importance of this therapeutic modality.”

The event was supported by the Oligonulecotide Therapeutics Society, Secarna Pharmaceuticals GmbH & Co. KG, BioM (network organization of the biotechnology sector in Munich and in Bavaria), the sector association BIO Deutschland and MC Services AG.

For further information on the event and antisense oligonucleotides, please contact Secarna at info@secarna.com.

Secarna’s third generation LNAplusTM platform addresses the industry’s technical challenges

With multiple innovative antisense therapies in various stages of preclinical development for a broad range of therapeutic indications as well as the Company’s proprietary, customized, in-house, drug discovery platform LNAplusTM, Secarna successfully addresses the industry’s technical challenges.

The company’s LNAplusTM platform encompasses all aspects of drug discovery and preclinical development. The system’s main components are a proprietary bioinformatics modelling system (OligofyerTM), a best-in-class high throughput screening system, and bespoke target-specific functional assays created by the firm’s specialists. Latest generation technologies such as Secarna’s LNAplusTM are going to lead to innovative, highly specific, safe and efficacious therapies for challenging or currently undruggable targets.

About Antisense Oligonucleotides

Antisense oligonucleotides (ASOs) can control the expression of therapeutically relevant genes. ASOs modulate gene expression by the enzyme-dependent degradation of target messenger RNAs (mRNAs). To achieve this, the technology makes use of RNase H1, a cellular enzyme, to cleave the target RNA and consequently silence the expression of encoded proteins. By inhibiting the expression of disease-inducing and exacerbating proteins, ASOs have the potential to play a critical role as new therapeutics to treat diseases that have been non-treatable or have been treated ineffectively with currently available therapies.

About Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of preclinical development in the areas of immune-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna’s mission is to maximize the performance and output of its proprietary LNAplusTM antisense oligonucleotide discovery platform, to develop highly specific, safe, and efficacious antisense therapies for challenging or currently undruggable targets.

 

About Oligonucleotide Therapeutic Society

The Oligonucleotide Therapeutics Society (OTS) is an open, non-profit forum to foster academic and industry-based research in the development of oligonucleotide therapeutics.

OTS was founded in 2004 by an international group of renowned oligonucleotide scientists whose idea was to bring together the expertise from different angles of oligonucleotide research, to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.

Contact

Jonas Renz
Managing Director and Co-Founder
Jonas.Renz@secarna.com

Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0)89 215 46 375

For media enquiries:

Anne Hennecke
MC Services AG
anne.hennecke@mc-services.eu
Tel.: +49 (0)211.52 92 52 22


19.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

APEIRON Announces Collaboration with Lead Discovery Center GmbH

DGAP-News: APEIRON Biologics AG / Key word(s): Alliance

19.09.2018 / 10:00

The issuer is solely responsible for the content of this announcement.


APEIRON Announces Collaboration with Lead Discovery Center GmbH

Alliance for medicinal chemistry optimization and development of
novel checkpoint blockade approach

Vienna, Austria, 19 September 2018: APEIRON Biologics AG, an Austrian company focused on cancer immunotherapy, today announced a collaboration agreement with the Lead Discovery Center GmbH (LDC), a translational research organization established in 2008 by Max Planck Innovation, to develop novel immune checkpoint modulators. The two companies will perform drug discovery activities to optimize and develop novel small molecules addressing immune checkpoints, important gatekeepers in cancer immunity. All molecules deriving from this collaboration are proprietary to APEIRON and will strengthen APEIRON’s development pipeline.

Peter Llewellyn-Davies, Chief Executive Officer of APEIRON Biologics, said: “We are delighted to announce this alliance with LDC. APEIRON has an excellent and broad pipeline being pursued to develop therapies both aiming at targeting tumor cells and stimulating the immune system to fight cancer. With its track record in pharmaceutical drug discovery and long-standing small molecule expertise, the LDC is the ideal partner for us to identify new drug candidates and to further accelerate the development of new immune checkpoint modulators. I am confident our combined R&D forces will drive our technology in the field of immune-oncology forward and strengthen our product candidate portfolio in small molecules.”

The LDC will use its expertise in small molecule drug discovery to design and optimize new substances, which can activate immune cells and drive their anti-tumor activity. The medicinal chemistry efforts are based on a new substance class, which was identified by phenotypic screening, discovered in APEIRON’s cooperation with Evotec AG, and has shown to activate peripheral blood mononuclear cells (PBMCs). The intellectual property generated under the terms of the agreement solely belongs to APEIRON. The LDC will receive research funding during the collaboration period and is eligible to an upfront payment, milestone payments and royalties. Further financial details of the collaboration agreement were not disclosed.

The work will be carried out at both APEIRON’s R&D facilities in Vienna, Austria, and in the LDC laboratories in Dortmund, Germany. APEIRON will be responsible for further preclinical and clinical development of the product candidates, as well as subsequent marketing and commercialization.

About the LDC

The Lead Discovery Center (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the LDC is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential. The LDC sustains a strong partnership with the Max Planck Society and has performed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi-Sankyo, Qurient, Johnson&Johnson Innovation, Sotio, Gruenenthal and Roche, as well as leading translational drug discovery centres around the globe. Further information is available at www.lead-discovery.de.

About APEIRON Biologics AG

APEIRON is a privately-held commercial-stage biopharmaceutical company based in Vienna, Austria, focused on the discovery, development and commercialization of novel cancer immunotherapies. The company is leveraging its innovative therapeutic targets based on tumor-specific targeted approaches and the stimulation of the immune system via novel and proprietary unique mechanisms of action (checkpoint blockade) to eradicate cancer by engaging the human body’s natural defense mechanisms. For additional information please visit www.apeiron-biologics.com and follow us on Twitter @apeironbio.

For further information please contact:

APEIRON Biologics AG
Peter Llewellyn-Davies, CEO
Email: investors@apeiron-biologics.com
www.apeiron-biologics.com

Media Relations International
MC Services AG
Raimund Gabriel
T +49 89 210 228 0
Email: apeiron@mc-services.eu

Investor Relations
LifeSci Advisors, LLC
Chris Maggos
T +1 (646) 597 6989
Email: Chris@LifeSciAdvisors.com

Media Relations Austria
PR&D – Public Relations for Research & Education
T +43 1 505 70 44
Email: contact@prd.at

Public Relations LDC
Lead Discovery Center GmbH
T: +49 231 9742 7000
Email: pr@lead-discovery.de

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of APEIRON as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.


19.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Biofrontera AG: Biofrontera to present at the Baader Investment Conference

DGAP-News: Biofrontera AG / Key word(s): Conference

19.09.2018 / 09:28

The issuer is solely responsible for the content of this announcement.


Biofrontera to present at the Baader Investment Conference

Leverkusen, Germany, September 19, 2018 – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be participating at the Baader Investment Conference. The conference will take place from September 24-27, 2018 at the Sofitel Munich Bayerpost in Munich, Germany.

Prof. Dr. Hermann Lübbert, Biofrontera’s CEO, will provide an overview of the Company’s business during the live presentation and will be available for one-one meetings with investors during the conference.

Details for the presentation are as follows:
Date: Thursday, September 27, 2018
Time: 9:00 AM CEST
Venue: Sofitel Munich Bayerpost, Forum 3
-END-

For enquiries, please contact:

Biofrontera AG 
Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0
ir@biofrontera.com

IR UK: Seton Services 
Toni Vallen

+44 (0) 207 224 8468

IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas
+1 646-536-7035
+1 508-280-6592

 

About Biofrontera:

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera’s approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera’s ordinary shares are listed on the NASDAQ Capital Market under the symbol “BFRA”, and Biofrontera’s ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

Forward Looking Statements:

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate” and “intend,” among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section “Risk Factors,” and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

 


19.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq

 
End of News DGAP News Service

show this

Expedeon AG comments on recent share price development (news with additional features)

DGAP-News: Expedeon AG / Key word(s): Miscellaneous

18.09.2018 / 15:46

The issuer is solely responsible for the content of this announcement.


PRESS RELEASE
18 September 2018

/

Expedeon AG comments on recent share price development

Heidelberg, Germany and Cambridge, UK, 18 September 2018 Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard), said today that the management is not aware of any change in the operational or strategic position of the Company which would justify the recent movement in the share price. The Management Board members Dr. Heikki Lanckriet, CEO and CSO, and David Roth, CFO, consider the price reduction unwarranted and have taken the opportunity to purchase additional shares at this morning’s lower price level. Dr. Heikki Lanckriet continues to hold more than 3% of the Company’s stock, increasing his holding by 12,000 shares, while David Roth increased his holding to 113,500 shares with a purchase of 30,000 shares.

Expedeon continues to pursue its successful corporate strategy and day to day business of the Company is unaffected by today’s share price development. Revenue guidance for the financial year 2018 remains unchanged at EUR 13-14 million and the Company continues to expect an overall positive EBITDA for the year.

Dr. Heikki Lanckriet, CEO and CSO of Expedeon, commented: “The Management and Supervisory Board remain convinced of the success of the Expedeon business model and the creation of real value in the Company. We are proud of the achievements made during the last months and years and remain confident of this year being the most successful year in Expedeon’s history.”

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company’s core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon’s technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers’ development and commercialisation objectives. Expedeon’s products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=XMOYWPRUJC
Document title: Share_Eng


18.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Expedeon AG
Waldhofer Str. 102
69123 Heidelberg
Germany
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
E-mail: investors@expedeon.com
Internet: www.expedeon.com
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

STADA Arzneimittel AG: Voting results of the bondholders’ meeting concerning the STADA-Bond 2015/2022

DGAP-News: STADA Arzneimittel AG / Key word(s): Bond

18.09.2018 / 15:07

The issuer is solely responsible for the content of this announcement.


Bad Vilbel, 18 September 2018 – STADA Arzneimittel Aktiengesellschaft (“STADA” or the “Issuer“) today informed about the voting results of the meeting on 18 September 2018 (the “Bondholders’ Meeting“) of the bondholders (the “Bondholders“) of the EUR 300,000,000 1.750% bonds, due 2022, ISIN: XS1213831362, Common Code: 121383136, WKN: A14KJP (the “Bond“).

The purpose of today’s meeting was to set the basis for the Bondholders to participate in certain security interests. It was planned to pass a resolution on the instruction of the joint representative of the Bondholders to accede to the intercreditor agreement and on certain technical changes to the Bond’s terms and conditions.

Since the Bondholders’ Meeting did not reach the quorum required for the resolutions on these agenda items, no resolutions could be passed.

Further details of the Bondholders’ Meeting are available on the STADA website at www.stada.com/investor-relations/bonds.html.

About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de
Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:
STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de
Or visit us on the Internet at www.stada.com/investor-relations


18.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603-4689
Fax: +49 (0)6101 603- 215
E-mail: ir@stada.de
Internet: www.stada.de
ISIN: DE0007251803
WKN: 725180
Listed: Regulated Market in Dusseldorf, Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG announces strategic research collaboration with BluCon Biotech GmbH

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Strategic Company Decision

18.09.2018 / 08:59

The issuer is solely responsible for the content of this announcement.


Chemicals from Renewable Resources
BRAIN AG announces strategic research collaboration with BluCon Biotech GmbH

  • Joint R&D work aims at microbial strain development for the production of high-value chemicals including bioplastics
  • BRAIN provides comprehensive resources of its BioArchive and strain development expertise
  • BluCon Biotech contributes their respective production strains

Zwingenberg & Cologne, Germany
September 18, 2018

BRAIN AG, a German listed industrial biotechnology company, announces the start of a strategic research and development collaboration with BluCon Biotech GmbH. The objective of the joint research efforts is the identification and development of special microbial production strains. The collaboration will run several months with the option for extension and prolongation after reaching agreed milestones.

BluCon Biotech GmbH develops a consolidated bioprocess for the production of lactic acid from industrial or agricultural cellulosic waste based on the company’s proprietary bacteria. BluCon’s objective is to achieve very low production costs in order to allow the production of PLA-based bioplastic (poly lactic acid) at costs competitive to fossil fuel-based plastics.

The aim of the R&D collaboration is the further improvement of BluCon’s microorganisms with classical biotechnologies enabling them to produce within their metabolisms the required product in a highly efficient manner.

“BRAIN is a key player in the field of industrial biotechnology for developing innovative solutions and products for various industries. We are very glad that we now have BRAIN as a strategic partner for our ambitious programme to commercialize the BluCon platform”, says Dr Albrecht Läufer, CEO of BluCon Biotech GmbH.

“We are very experienced in industrial strain development programmes. Besides classical processes in aerobic production organisms, BRAIN also provides a comprehensive technology portfolio for the cultivation and genetic engineering of strictly anaerobic bacteria. We are committed to help our partner BluCon Biotech to improve the space time yield of the production strain in a short period of time”, says BRAIN’s Dr Martin Langer, EVP Corporate Development.

BžRžAžIžN
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
www.brain-biotech.de
 
Contact Investor Relations
Dr. Martin Langer
Executive Vice President
Corporate Development
Tel.: +49-6251-9331-16
E-Mail: ir@brain-biotech.de
 
Contact Media
Thomas Deichmann
Head of Public Relations
Tel.: +49-6251-9331-72
E-Mail: td@brain-biotech.de
 
 
 
BluCon Biotech GmbH
Dr. Albrecht Läufer, CEO
Nattermannallee 1
50829 Cologne, Germany
https://blucon-biotech.com/.
E-Mail: albrecht.laeufer@blucon-biotech.com
 

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this “Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN’s business model is based on two pillars – BioScience and BioIndustrial. The BioScience segment comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN’s own products and active product components. Further information is available at www.brain-biotech.de/en.

About BluCon

BluCon Biotech GmbH was established in June 2017 and is based at the Cologne BioCampus where it runs both research laboratories and offices. BluCon Biotech GmbH is currently developing a unique process that allows L-lactic acid to be produced at the lowest possible cost, which in turn paves the way for the production of PLA-based bioplastics (poly lactic acid) at prices competitive to their fossil fuel counterparts. Further information is available at https://blucon-biotech.com/.


18.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: ir@brain-biotech.de
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this